Scenarios of cost-savings associated with Oncotype DX® test-guided decisions for adjuvant chemotherapy in early breast cancer in Germany

Scenarios of cost-savings associated with Oncotype DX® test-guided decisions for adjuvant chemotherapy in early breast cancer in Germany

Bibliographic Details
Main Authors:	M.P. Lux, L. Brandt, K.H. Herrmann, T. Ecker
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621001260

Similar Items

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2022-01-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
by: Luca Licata, et al.
Published: (2023-06-01)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
by: Kathleen Iles, et al.
Published: (2022-03-01)

Oncotype DX Recurrence Score in premenopausal women
by: Shiliang Zhang, et al.
Published: (2022-03-01)

Oncotype DX: Where Does It Stand in India?
by: Atul Batra, et al.
Published: (2019-07-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Oncotype Dx Results in Multiple Primary Breast Cancers
by: Michael J. Toole, et al.
Published: (2014-01-01)

Oncotype Dx Results in Multiple Primary Breast Cancers
by: Michael J. Toole, et al.
Published: (2014-01-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
by: Daniel A. Goldstein, et al.
Published: (2020-07-01)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
by: Beate Jahn, et al.
Published: (2017-10-01)

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

MiRNA expression deregulation correlates with the Oncotype DX® DCIS score
by: Olivier Loudig, et al.
Published: (2022-09-01)

The Oncotype DX ® assay use in breast cancer in an Australian institutional setting
by: J.D.W. Choi, et al.
Published: (2021-04-01)

Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score
by: Vikram R. Shaw, et al.
Published: (2023-06-01)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
by: Matthew G. Davey, et al.
Published: (2022-07-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
by: Aditya K. Sengupta, et al.
Published: (2020-11-01)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
by: Çağlar Ünal, et al.
Published: (2023-06-01)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
by: Richard Buus, et al.
Published: (2021-02-01)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
by: Valeria Romeo, et al.
Published: (2023-03-01)

Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review
by: Ang Zheng, et al.
Published: (2019-05-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.
by: Matthew Northgraves, et al.
Published: (2024-01-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022-09-01)

Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay
by: Michael A. Jacobs, et al.
Published: (2020-09-01)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
by: Ran Song, et al.
Published: (2023-09-01)

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
by: Zsuzsanna Varga, et al.
Published: (2013-01-01)

Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
by: Jon Whitney, et al.
Published: (2018-05-01)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
by: Nickolas Stabellini, et al.
Published: (2023-04-01)

P168 OncotypeDX RS new TAILORx cut-offs: omitting Chemotherapy in more patients aged >50 years with Early Breast Cancer
by: C. MarKopoulos, et al.
Published: (2023-03-01)

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study
by: Leandro Jonata Carvalho Oliveira, et al.
Published: (2022-12-01)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
Published: (2013-01-01)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas.
by: Rajyasree Emmadi, et al.
Published: (2015-01-01)

Association between oncotype DX genomic prostate score and final tumor pathology report after radical prostatectomy
by: C. Chew, et al.
Published: (2020-07-01)

Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
by: Haojia Li, et al.
Published: (2019-10-01)

How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study
by: Gahie Nam MD, et al.
Published: (2021-10-01)

Benefits and Applications of Oncotype DX Breast Recurrence Score Testing among Breast Cancer Patients: Current Recommendations and Controversies.
by: Elena-Diana Chiru, et al.
Published: (2023-06-01)